The ACC Preclinical Research Platform for Precision Oncology

Recruiting

• Conditions: Solid Tumor; Hematologic Neoplasms

• Registration Number: NCT06339541
• Lead Sponsor: Fondazione del Piemonte per l'Oncologia

Brief Summary

The ACC Preclinical Research Platform for Precision Oncology is a retrospective and prospective observational study focused on the implementation and validation of the application of PDCM (Patient Derived Cancer Models) generated from tissues or cells of patients with neoplastic disease, as a tool to improve molecular and biological knowledge of tumours and to test the efficacy and sensitivity of pharmacological treatments.

Detailed Description

This is a retrospective and prospective observational study, focused on the implementation and validation of the application of PDCM, generated from tissue or cells of patients, including paediatric patients, with solid and haematological malignancies, as a tool to improve molecular and biological knowledge of tumours and to test the efficacy and sensitivity of pharmacological treatments.

An up-to-date database of all PDCMs available at the participating italian hospitals will be generated and enriched with new models generated during the course of the project. The sharing of models and procedures between the different hospitals will facilitate their molecular and phenotypic characterisation, also in parallel with the tumours of origin, as well as their validation as tools for testing the efficacy of drugs for precision medicine. By establishing common workflows and standards and performing cross-validation experiments it is planned to build a network of reference centres as a resource for drug screening on 2D and 3D models.

Study Timeline

• Study Start: 2023-06-05
• Status Verified: 2024-03
• Study First Submitted: 2024-03-25
• Study First Submitted QC: 2024-03-25
• Last Update Submitted: 2024-03-25
• Study First Posted: 2024-04-01
• Last Update Posted: 2024-04-01
• Primary Completion: 2024-06-01
• Study Completion: 2024-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• Patients, including paediatric patients, with solid and haematological malignancies for whom tissue or tumour cell material is available.

Read More

Exclusion Criteria

• none

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
number of PDCM (patient derived cancer models)	12 months	PDCM will be generated from tissues and cells
number of Whole Exome Sequencing (WES) e RNA-seq performed	12 months	WES and RNA seq will be performed on tissues and blood

Secondary Outcome Measures

Name	Time	Method
number of PDCM shared within the network	12 months	PDCM will be generated from tissues and cells and shared within the network

Trial Locations

Locations (1)

Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo; 🇮🇹 Candiolo, Turin, Italy